Tadeusz R.
- Country
- Poland
- Department
- Oddział Hematologii Ogólnej i Chorób Wewnętrznych
Research Overview
- Phase 1b Multicenter Open-label Study of Acalabrutinib with Bendamustine and Rituximab or Venetoclax and Rituximab in Mantle Cell Lymphoma
- A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP in Participants with DLBCL (waveLINE)
- Phase 3 Randomized Study of Tirabrutinib Versus Rituximab-Temozolomide in Relapsed/Refractory Primary Central Nervous System Lymphoma
Data & Insights
Has run more than one trial at 313 of 520 partner sites.
Specializations
Lymphoid Malignancies
The investigator specializes in treating B-cell lymphoid malignancies, with particular emphasis on chronic lymphocytic leukemia (CLL) and various lymphoma subtypes. Their research encompasses novel therapeutic approaches using targeted agents and combination strategies.
- Chronic Lymphocytic Leukemia Management
- B-Cell Lymphoma Treatment
- Mantle Cell Lymphoma
Multiple Myeloma
The investigator focuses on developing treatment strategies for multiple myeloma, including research into novel drug combinations and approaches for both newly diagnosed and relapsed/refractory disease states.
- Newly Diagnosed Multiple Myeloma
- Relapsed/Refractory Disease
- Combination Therapy Approaches
Hematologic Disorders
The investigator's expertise extends to various hematologic conditions, including research in polycythemia vera and autoimmune hemolytic anemia. Their work includes investigation of novel therapeutic agents for these conditions.
- Blood Disorders
- Myeloproliferative Neoplasms
- Autoimmune Blood Conditions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.